eyeforpharma Barcelona 2018

eyeforpharma13 - 15 March 2018, Barcelona, Spain.
eyeforpharma Barcelona is an annual pilgrimage for pharma's executives who want to map their future commercial success. Now it has become the place to map a different journey, that of our customers and patients. Gain their trust and serve as their guiding light towards better outcomes for all.

One eyeforpharma Barcelona. 9 in-depth commercial pharma conferences on the key issues of 2018 and beyond. This year we will bring you unrivalled expertise, patient insights, real-world data - the building blocks to deliver innovative and complete healthcare solutions, to make a real difference to the lives of patients and customers.

1. A Vision for the Future
2. Commercial Model Innovation
3. Talent and Diversity
4. Patient Partnerships
5. Advances in Customer Engagement
6. Digital Innovation and Analytics
7. Sales Force Effectiveness
8. Interactive Sessions - you lead the discussion
9. Medical Affairs

Why you can't miss Barcelona 2018

Barcelona is not a normal conference. Our mission is to create the mass movement we need across the pharma industry.

We must ask ourselves is it possible for a pharma company to be a credible, go-to source of health knowledge? Is it possible to be trusted, respected and admired? Despite having all the resources, expertise and reach, pharmaceutical companies are still a long way from this. To get there, each company must better appreciate the value it provides - and to have a greater vision for the value it can provide.

2018 will guarantee:

  • Collaborative setting: Our aim to ensure your key stakeholder are present to advance partnerships with healthcare, technology, patient and patient association
  • An Inspiring Agenda: As you undergo a commercial evolution we will cover 9 themes, provide intimate workshops and keynote sessions to help direct your journey
  • 1200+ in attendance: If you are looking for one commercial meeting to attend in 2018, Barcelona will be sure to give you the most senior networking opportunities possible
  • NO Sales Pitch: this is an independently researched event committed to equipping you with the techniques and expertise to drive your business. You will take-away actionable insights proven to drive your commercial strategy
  • More Than 80 Executive-level Thought Leaders sharing their experience and knowledge. Take this opportunity to transform your organisation, become truly customer-centric and improve healthcare outcomes.

Join the most forward-thinking speakers from across Europe including C-Level, VPs and Industry leaders from J&J, Bayer Pharmaceuticals, Lilly Bio Medicines, Teva, Takeda and MSD. This is the ideal place to ensure your commercial strategy is prepared for 2018 and beyond.

World Pharma News readers can benefit from an exclusive discount - save €200 using the unique discount code WPN200 when you register online here.

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the centre.

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Probiotics can protect the skeletons of older wome…

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteri...

Alzheimer's breakthrough: Brain metals that may dr…

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegen...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

In mice, stem cells seem to work in fighting obesi…

Obesity is an increasing global health problem associated with several comorbidities and a high risk of mortality. A wide spectrum of interventions has been proposed for ...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

FDA takes steps to foster greater efficiency in bi…

Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as w...

Research shows how a moderate dose of alcohol prot…

For at least 20 years, research has shown that for many people, moderate consumption of alcohol can protect the heart, but the reason for this is poorly understood. A stu...

'Kiss of death' cancer

It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negativ...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...